Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-Avibactam plus Metronidazole vs Meropenem in cIAI (RECLAIM3)
NCT01726023Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2013
- Primary completion
- Mar 2015
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of ceftazidime + avibactam in Intra-abdominal infection (IAI) (2 arms), sponsored by Pfizer. Primary endpoint: Proportion of Patients With Clinical Cure. Started Jan 2013; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT01726023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01726023.